
Release date: 2026-05-19 15:55:27 Article From: Lucius Laos Recommended: 14
Crizotinib is a prescription medication used to treat non-small cell lung cancer (NSCLC) caused by defects in the anaplastic lymphoma kinase (ALK) gene or the ROS1 gene, and that has spread to other parts of the body. Depending on the abnormal gene, this type of lung cancer is called ALK-positive or ROS1-positive. In 2011, Crizotinib became the first drug for patients with ALK-positive metastatic NSCLC; today, it is also indicated for ROS1-positive patients. It is not known whether Crizotinib is safe and effective in pediatric patients.
There are many types of lung cancer, and not all types are treated with the same medication. Crizotinib specifically targets non-small cell lung cancer driven by defects in the ALK or ROS1 genes. These genetic defects cause cancer cells to grow and spread abnormally. Crizotinib works by inhibiting the activity of these abnormal kinases, thereby blocking cancer cell signaling pathways and controlling tumor growth. In clinical studies, for most patients with ALK-positive or ROS1-positive metastatic NSCLC, Crizotinib was able to shrink tumors or slow their growth for a period of time. It is important to understand that Crizotinib does not make the cancer completely disappear, but it can provide patients with valuable periods of disease stability.
Before starting Crizotinib, patients must fully discuss their entire health status and medication use with their healthcare provider. It is especially important to inform about: any liver or kidney problems, lung disease, heart problems (such as long QT syndrome), vision or eye disorders, and whether you are pregnant, plan to become pregnant, or are breastfeeding. Because Crizotinib may cause harm to a fetus, women of childbearing potential must use effective contraception during treatment and for 45 days after the last dose; male patients with female partners of childbearing potential should use condoms during treatment and for 90 days after the last dose. Additionally, tell your doctor about all medications you are taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements, to avoid potential drug interactions.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3472025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5502024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3352025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3472025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3252025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3852025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3222025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643